The NDC
considers the following Rx
algorithm published by the ACP as somewhat
harmful and misguided due to
its recommendation of (1) KATP- channel
antagonists which
cause coronary vasoconstriction (sulfonylureas)
as first line therapy (2) A1c action points of
>7% which in
the absence of any corroberating data appear
overly tight and may lead to excessive
hypoglycemia, morbidity, and mortality and (3)
triple therapy which has no long-term
safety data to recommend it:-
|